SCHEMBL923315

SCHEMBL923315

Clc1cccc(Nc2nc(C3CC3)nc3sc4ccccc4c23)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 4/20 0.41
ABCG2 Q9UNQ0 2/20 0.41
FADS1 O60427 4/20 0.41
EGFR P00533 4/20 0.41
LCK P06239 1/20 0.40
ABL1 P00519 1/20 0.40
ABL2 P42684 1/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
CYP2C19 P33261 1/20 0.40
PDE1A P54750 1/20 0.40
PDE1B Q01064 1/20 0.40
PDE3B Q13370 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL923415 0.87 EPAS1 (0.49) PDE5AABCG2EGFREPAS1
SCHEMBL923119 0.87 MAPT (0.44) PDE5AABCG2EGFRMAPTSMN1; SMN2
SCHEMBL924677 0.87 PDE5A (0.43) PDE5AABCG2FADS1EGFRKDM4E
SCHEMBL923398 0.84 EPAS1 (0.52) PDE5AABCG2EGFRKDM4EALDH1A1
SCHEMBL922804 0.79 MKNK1 (0.66) EGFRMAPTMKNK1
SCHEMBL924526 0.77 MKNK1 (0.60) FADS1EGFRLCKABL1ABL2
SCHEMBL12903928 0.71 ELANE (0.36) KDM4EALDH1A1MAPTHPGDALOX15
SCHEMBL6764615 0.68 PDE10A (0.40) PDE5AALDH1A1SMN1; SMN2POLB
SCHEMBL7403578 0.68 PDE5A (0.46) PDE5AEGFRALDH1A1HPGDSMN1; SMN2
SCHEMBL6657678 0.68 EGLN1 (0.39) KDM4EALDH1A1MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8802849-B2 Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use VICHEM CHEMIE KUTATÓ KFT. (HU) 2014-08-12 US claimed
EP-2257554-A1 TRICYCLIC BENZOÝ4,5¨THIENO-Ý2,3-D¨PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE Vichem Chemie Kutató KFT (HU) 2010-12-08 EP claimed
WO-2009104026-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE VICHEM CHEMIE KUTATÓ KFT (HU) 2009-08-27 WO claimed
US-8802849-B2 Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use VICHEM CHEMIE KUTATÓ KFT. (HU) 2014-08-12 US disclosed
US-20110015214-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE VICHEM CHEMIE KUTATO KFT. (HU) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015214-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE TYMS, TYMP, DPYD PDE5A 2234/4885ABCG2 17/4885FADS1 3851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.